PATH swells in size

Xconomy outlines the rapid growth of Seattle-based PATH, which has used millions in grants from the Gates Foundation to pursue research into new vaccines. Since 2000, PATH has grown from 240 employees to a staff of 775 and its annual budget has hit $240 million. Report

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.